WILLINGMED
Latest round
- Series B
Last raised
- Apr 2023
Total raised
- $15M
Investors
- 4
About WILLINGMED
Established in 2019 and based in Beijing, China, WILLINGMED is a medical service provider that focuses on an accurate diagnosis of infection. Dr. Yan Zhang, the founder, and CEO of the company, served as the dean of the Institute of Translational Medicine at Boao Biology and served as the technical research and development director of the scientific research management center at Boao Jingdian. The core team has nearly 20 years of experience in the precision testing of pathogenic microorganisms. It has more than 40 intellectual property rights as of 2023., Ltd. The company engages in the development of the accurate diagnosis of infection. Its main products include Plseq (Pathogen Identification Sequencing) metagenomic testing and WYSP high-throughput automation workstation. WYSP high-throughput automation workstation provides full-process intelligent automation services from sample preparation, library construction, and on-machine sequencing to clinical report generation.
Who invested in WILLINGMED
4 investors across 2 rounds
See all investors in WILLINGMED
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about WILLINGMED
Who invested in WILLINGMED?
WILLINGMED has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has WILLINGMED raised?
WILLINGMED has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did WILLINGMED last raise money?
WILLINGMED's most recent round on record is a Series B, in Apr 2023.
What does WILLINGMED do?
Established in 2019 and based in Beijing, China, WILLINGMED is a medical service provider that focuses on an accurate diagnosis of infection.
Where is WILLINGMED headquartered?
WILLINGMED is headquartered in Beijing, China.
Which VCs invest in companies like WILLINGMED?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at WILLINGMED's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like WILLINGMED? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.